menu
    • menu
    [{"orgOrder":0,"company":"PanTheryx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"Bifidobacterium","moa":"||Undisclosed","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"PanTheryx","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Solution","sponsorNew":"PanTheryx \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"PanTheryx \/ Undisclosed"},{"orgOrder":0,"company":"PanTheryx","sponsor":"PanTheryx","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"NETHERLANDS","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"E1392-75-2A","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"PanTheryx","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PanTheryx \/ PanTheryx","highestDevelopmentStatusID":"1","companyTruncated":"PanTheryx \/ PanTheryx"},{"orgOrder":0,"company":"PanTheryx","sponsor":"PanTheryx","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Acquisition","leadProduct":"Goodgut","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"PanTheryx","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PanTheryx \/ PanTheryx","highestDevelopmentStatusID":"15","companyTruncated":"PanTheryx \/ PanTheryx"},{"orgOrder":0,"company":"PanTheryx","sponsor":"PanTheryx","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Dietary Supplement","year":"2015","type":"Inapplicable","leadProduct":"PTM202","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"PanTheryx","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PanTheryx \/ PanTheryx","highestDevelopmentStatusID":"1","companyTruncated":"PanTheryx \/ PanTheryx"}]

    Find Clinical Drug Pipeline Developments & Deals by PanTheryx

    Menu

    PanTheryx

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            PanTheryx

                            U.S.A arrow
                            Cell Bio
                            Not Confirmed

                            PanTheryx

                            U.S.A arrow
                            Cell Bio
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bifidobacterium,Lactobacillus Rhamnosus

                            Therapeutic Area : Gastroenterology

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            TruBiotics® Grows Its Family: New Baby Drops Feature Clinically Researched Probiotic Strain BB-12® Shown to ...

                            Details : Kids Chewable probiotic supplements, TruBiotics (Bifidobacterium) and Lactobacillus launched by company, the two most-clinically researched probiotic types to support digestive and immune heath for children.

                            Product Name : TruBiotics

                            Product Type : Microorganism

                            Upfront Cash : Inapplicable

                            March 02, 2022

                            Lead Product(s) : Bifidobacterium,Lactobacillus Rhamnosus

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            PanTheryx

                            U.S.A arrow
                            Cell Bio
                            Not Confirmed

                            PanTheryx

                            U.S.A arrow
                            Cell Bio
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Goodgut

                            Therapeutic Area : Gastroenterology

                            Study Phase : Approved FDF

                            Recipient : Greenteaspoon

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            PanTheryx Acquires Goodgut® and Preliva® Brands from Greenteaspoon Inc.

                            Details : The acquisition adds a high-quality prebiotic to the PanTheryx product lines that already include bovine colostrum for digestive and immune human health.

                            Product Name : Goodgut

                            Product Type : Vitamins/Minerals/Inorganic Salts

                            Upfront Cash : Undisclosed

                            October 14, 2020

                            Lead Product(s) : Goodgut

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Approved FDF

                            Recipient : Greenteaspoon

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            PanTheryx

                            U.S.A arrow
                            Cell Bio
                            Not Confirmed

                            PanTheryx

                            U.S.A arrow
                            Cell Bio
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : E1392-75-2A

                            Therapeutic Area : Gastroenterology

                            Study Phase : Undisclosed

                            Recipient : NIZO Food Research

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            PTM202 and Modulation of Host Resistance to Diarrheagenic E. Coli

                            Details : E1392-75-2A is a drug candidate, which is currently being evaluated in clinical studies for the treatment of Diarrhea.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            October 04, 2017

                            Lead Product(s) : E1392-75-2A

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Undisclosed

                            Recipient : NIZO Food Research

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            PanTheryx

                            U.S.A arrow
                            Cell Bio
                            Not Confirmed

                            PanTheryx

                            U.S.A arrow
                            Cell Bio
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PTM202

                            Therapeutic Area : Gastroenterology

                            Study Phase : Undisclosed

                            Recipient : University of Colorado, Denver

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Impact of the Nutritional Product PTM202 on Acute and Long-Term Recovery From Childhood Diarrheal Disease

                            Details : PTM202 is a Dietary Supplement drug candidate, which is currently being evaluated in clinical studies for the treatment of Diarrhea.

                            Product Name : Undisclosed

                            Product Type : Dietary Supplement

                            Upfront Cash : Inapplicable

                            March 11, 2015

                            Lead Product(s) : PTM202

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Undisclosed

                            Recipient : University of Colorado, Denver

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth